BRISBANE: AnteoTech Ltd has signed a non-binding Heads of Agreement with Merck to co-develop AnteoBind activated Europium particles for the rapidly growing global point of care (PoC) diagnostic testing market. The products will harness Merck’s full range of Europium particles activated with AnteoBind to offer an advanced toolset for assay developers. The combined products will…